Nasal spray is administered through the nostrils, delivering drugs directly to the nasal passages and sinuses. One primary application of the nasal spray market is treating allergic rhinitis. Nasal sprays containing corticosteroids, antihistamines, or decongestants are commonly used to alleviate symptoms such as nasal congestion, runny nose, and sneezing caused by allergic reactions to pollen, dust, or pet dander. These sprays provide targeted relief by delivering medication directly to the nasal passages, offering a convenient and effective solution for managing allergic rhinitis symptoms worldwide.
Global Nasal Spray Market is projected to reach USD 38,026.75 million by 2030, with a CAGR of 6.7% during the forecast period of 2023-2030.
To know more, visit https://www.databridgemarketresearch.com/de/reports/global-nasal-spray-market
Below are the Top Nasal Spray Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
GlaxoSmithKline plc
|
GlaxoSmithKline plc, a leading pharmaceutical company, offers a range of nasal spray products for various therapeutic areas, including respiratory health. With a strong focus on research and development, GlaxoSmithKline plc continually innovates to address the evolving needs of the nasal spray market, particularly in treating respiratory conditions such as allergic rhinitis and nasal congestion.
|
|
South America, North America, Asia-Pacific, Europe, and Middle East and Africa
|
In October 2022, GSK plc and Tempus, a US-based precision medicine company, entered into a three-year collaboration agreement that provides GSK access to Tempus’ AI-enabled platform, including its library of de-identified patient data. Through its leading Artificial Intelligence and Machine Learning (AI/ML) capability, GSK will work with Tempus to improve clinical trial design, speed up enrolment, and identify drug targets. The collaboration would help the company expand.
|
|
2.
|
Pfizer Inc.
|
Pfizer is a significant player in the nasal spray market and is known for its innovative products targeting respiratory disorders and allergies. The company's extensive portfolio includes nasal sprays to relieve congestion, runny nose, and sneezing. Pfizer's commitment to quality and efficacy makes it a trusted choice for consumers seeking effective nasal spray solutions.
|
|
South America, North America, Asia-Pacific, Europe, and Middle East and Africa
|
In March 2023, Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET (zavegepant), the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine with or without aura in adults. In its pivotal Phase 3 study, ZAVZPRET was statistically superior to placebo on the co-primary endpoints of pain freedom and freedom from most bothersome symptoms at two hours post-dose. This product approval has helped the company expand its product portfolio.
|
|
3.
|
Emergent
|
Emergent is a pharmaceutical company specializing in developing and manufacturing nasal spray products for prescription and over-the-counter use. With a focus on quality control and regulatory compliance, Emergent offers a range of nasal sprays for conditions such as allergies, sinusitis, and cold symptoms, catering to the market's diverse needs.
|
|
South America, North America, Asia-Pacific, Europe
|
In February 2023, Emergent received FDA approval for NARCAN nasal spray, the first 4 mg naloxone nasal spray to be switched from prescription to over-the-counter. This approval has helped the company expand its product sales across the U.S.
|
|
4.
|
Sandoz International Gmbh
|
Sandoz is a key player in the nasal spray market, providing high-quality generic and branded options. The company's nasal spray portfolio includes products for allergy relief, nasal congestion, and other respiratory conditions. Sandoz's focus on affordability and accessibility makes its nasal sprays popular among consumers worldwide.
|
|
South America, North America, Asia-Pacific, Europe, and Middle East and Africa
|
In January 2023, Sandoz, the global leader in off-patent (generic and biosimilar) medicines, signed an agreement to acquire worldwide product rights for leading systemic antifungal agent Mycamine (micafungin sodium, Funguard in Japan) from Astellas. This acquisition would help the company in the growing portfolio of anti-infective therapies to combat the spread of antimicrobial resistance.
|
|
5.
|
Catalent, Inc
|
Catalent is a leading provider of drug delivery solutions, including nasal spray development and manufacturing services. The company collaborates with pharmaceutical clients to bring innovative nasal spray products to market efficiently and cost-effectively. Catalent's expertise in formulation development and manufacturing technologies contributes to the success of nasal spray products across various therapeutic areas.
|
|
South America, North America, Asia-Pacific, Europe
|
In March 2023, Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, and Bhami Research Laboratory (BRL), announced a licensing agreement that would provide Catalent with access to BRL’s formulation technology to help enable the subcutaneous delivery of high-concentration biologic therapies. This collaboration agreement would help the company expand its business.
|
Conclusion
The global nasal spray market is poised for substantial growth, driven by increasing awareness of respiratory health and rising demand for effective allergy relief. GlaxoSmithKline plc, Pfizer Inc., Emergent, Sandoz International GmbH, and Catalent, Inc. are at the forefront, offering innovative nasal spray solutions tailored to diverse therapeutic needs. These companies' commitment to research, development, and quality assurance underscores their pivotal role in providing convenient and effective treatments for allergic rhinitis and other respiratory conditions worldwide. As the market expands, collaboration and innovation will remain crucial for meeting evolving consumer demands and driving further advancements in nasal spray technology.
